Investor Area

News

Announcements by type

  • Presentation

  • Corporate

  • Newsletter

  • Regulatory

  • Financial

  • Clinical

  • Reset

 
Thursday, 10 September 2020

SCENESSE® in DNA Repair

CLINUVEL to confirm cellular DNA repair in rare disease xeroderma pigmentosum (XP) A separate media release – in simple non-technical terms – has been lodged outlining the aims and objectivesof the DNA Repair Program. CLINUVEL will post background information on XP to its social media channels:Twitter | Facebook | Instagram | LinkedIn EXECUTIVE SUMMARY CLINUVEL […]

Download PDF
 
 

On 27 August 2020 CLINUVEL released its Preliminary Financial Report for FY2020. CFO Darren Keamy and CEO and Managing Director Dr Philippe Wolgen speak with Head of Investor Relations, Malcolm Bull, following the results release. A corporate presentation was also released on 27 August and can be accessed here.

Download PDF
 
 
Tuesday, 01 September 2020

Proposed issue of Securities

Download PDF

Download PDF
 
 

CLINUVEL OPENS VALLAURIX R&D CENTRE IN SINGAPORE Bespoke Research & Development Centre to advance innovative pharmaceutical and OTC products The CLINUVEL Group today announced the opening of its state-of-the-art centralised Research & Development Centre in Singapore, operated by CLINUVEL subsidiary VALLAURIX PTE Ltd. The extensive bespoke analytical and biological laboratories and offices will house and […]

Download PDF
 
 

Opening of VALLAURIX R&D facilities in Singapore

Download PDF
 
 

Download PDF Previous Next

Download PDF
 
 
Thursday, 27 August 2020

CLINUVEL Declares Full Year Dividend

CLINUVEL Declares Full Year Dividend Dividend/Distribution – CUV

Download PDF
 
 
Thursday, 27 August 2020

CLINUVEL Full Year Results

CLINUVEL Full Year Results 2020

Download PDF
 
 

Appendix 4E and Preliminary Financial Report 2020

Download PDF
 
 
Friday, 31 July 2020

Appendix 4C – quarterly

CLINUVEL PHARMACEUTICALS LTD today announced its Appendix 4C – Quarterly Cashflow Report and Activity Report for the period 01 April to 30 June 2020. All figures are rounded and reported in Australian dollars. Key Highlights: •  Cash receipts $10,403,000 over the quarter •  Net cash flow of $7,175,000 •  Cash and equivalents on hand increased […]

Download PDF
 
 
Thursday, 23 July 2020

Kommuniqué IV

Liebe Aktionäre, Freunde, Es stellt sich eine neue Welt dar, die darauf hinweist, dass das Virus nicht so leicht zu beseitigen sein wird. Waehrend wir es akzeptieren, einen Modus der Koexistenz zu finden, muessen wir für die mehr als 600.000 Menschen, die ihr Leben verloren haben und unzählige weitere, die von dieser Pandemie betroffen sind, […]

Download PDF
 
 
Wednesday, 22 July 2020

CLINUVEL Newsletter

Communiqué IV, 2020 – 22 July 2020 Dear shareholders, friends, As a new world presents itself indicating that the virus will not easily be eliminated as we are accepting to find a modus co-existentiae, albeit we need to pause for the more than 600,000 people who have lost their lives and countless more impacted by […]

Download PDF
 

Dearest Shareholders, As the incoming Chair of the Company, in short letters I will try to provide you with updates and inform you about our business.[...]

Download PDF
 

 CLINUVEL PHARMACEUTICALS LTD today announced that Mr Stan McLiesh will retire from his role as Non-Executive Director and Chair of the Board on 30 November 2019. Non-Executive Director Mr Willem Blijdorp has been elected Chair …

Download PDF
 
Thursday, 17 October 2019

CLINUVEL Newsletter

  In this News Communiqué VII, we pause to reflect on the outstanding US regulatory outcome and look back one last time at all the events which led to the long-desired outcome on 8 October, the …

Download PDF
 
Tuesday, 15 October 2019

Chair Letter to Shareholders

  Dear All, In my career in life sciences, I have served on public Boards, was part of the management team that led CSL to its position and oversaw several executive transitions in our beloved Company, first …

Download PDF
 
Tuesday, 20 August 2019

CLINUVEL Newsletter - August 2019

  Dear patients, shareholders, friends, In this News Communiqué VI for the year we report further on CLINUVEL’s regulatory progress in the US and the latest quarterly results for the period ending 30 June 2019. [...]

Download PDF
 
Thursday, 11 July 2019

CLINUVEL Newsletter - July 2019

  In this Communiqué we turn our attention to the most recent news communicated to the Company on 31 May by the US Food and Drug Administration (FDA): an extension of the scientific review time for …

Download PDF
 
Thursday, 02 May 2019

CLINUVEL Newsletter

02 May 2019  Dear patients, shareholders, friends,In this Communiqué we concentrate on CLINUVEL’s programs and US market access for SCENESSE®.As the European season unfolds, we report on the back of quarterly financials (released 30 April) …

Download PDF
 
Wednesday, 24 April 2019

Chair Letter to Shareholders

24 April 2019   Dear All,On a continent where very few biotechnology and pharmaceutical companies have ever succeeded in taking a first-in-class and first-in-line therapy from concept to commercialisation, CLINUVEL has all the makings of becoming …

Download PDF
 
Wednesday, 20 March 2019

CLINUVEL Newsletter – March 2019

20 March 2019  Dear patients, shareholders, friends,In the third Communiqué we are reviewing our EU operations, the impact of Brexit and looking at the year ahead. FDA REVIEWAt the time of print CLINUVEL will find itself …

Download PDF
 
Tuesday, 12 February 2019

CLINUVEL Vitiligo Communiqué II

12 February 2019   In the second Communiqué we look closer at the role of narrowband UVB (NB-UVB) as the only standard of care at present in vitiligo, both the segmental and generalised form of the disease. …

Download PDF